Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 71-76

  Kakolyris, S ^a   Kouroussis, Ch ^a   Souglakos, J ^a   Agelaki, S ^a   Kalbakis, K ^a   Vardakis, N ^a   Vamvakas, L ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatin; CPT 11; NSCLC; Salvage treatment

Indexed keywords

CISPLATIN; IRINOTECAN; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0035199379     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00384-1     Document Type: Conference Paper

References (32)

1. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
2. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
3. A phase II study of CPT-11, a new camptothecin derivative for previously untreated non-small cell lung cancer
4. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
5. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a Phase II study
6. Antitumor activity of 7-ethyl-10[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors
7. Identification of mammalian DNA topoisomerase as an intracellular target of the anticancer drug camptothecin
8. On the mechanism of topoisomease I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex
9. DNA topoisomerases: enzymes that catalyze the breaking and rejoining of DNA
10. DNA Topoisomerases
11. Irinotecan (CPT-11): current status and perspectives
12. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue
13. Antitumour effect of CPT-11, a new derivative of camptothecin against pleiotropic drug-resistant tumour in vitro and in vivo
14. Enhanced antitumour efficacy of a combination of CPT-11, a new derivative of camptothecin, and P against lung tumour xenografts
15. Effects of CPT-11 in combination with other anticancer agents in culture
16. CPT-11 in combination with P for advanced non-small cell lung cancer
17. Phase I and pharmacologic study of irinotecan in combination with P for advanced lung cancer
18. Phase I study of irinotecan and P with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer
19. Phase II study of irinotecan and infusional P with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer
20. Phase II study of irinotecan in combination with P as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
21. Fractionated administration of P and irinotecan in patients with stage IIIB and IV non-small cell lung cancer (NSCLC)
22. Preliminary results of a multicenter phase II trial of weekly P and irinotecan in patients with advanced non-small cell lung cancer (NSCLC). A Vanderbilt Cancer Center affiliate network study
23. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
24. Non-parametric estimation from incomplete observations
25. Docetaxel in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a milticenter trial
26. P-gemcitabine combination in advanced non-small cell lung cancer: a phase II study
27. Single agent docetaxel in patients with refractory non-small cell lung cancer
28. Randomized phase III trial of docetaxel vs. vinorelbine or ifosphamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens
29. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after P- or docetaxel-based chemotherapy